投資
124年投資退出
43想告知投資者類似拳擊手資本關於你的公司嗎?
提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏
最新的拳擊手資本新聞
2023年3月24日,
2023年3月23日耀斑療法Inc .生物科技公司針對轉錄因子發現精密癌症和其他疾病的藥物,今天宣布了一項1.23億美元共同融資GordonMD全球投資公司和輝瑞製藥企業參與,從現有投資者拳擊手資本Casdin資本,黃昏資產管理、金融顧問,Invus Nextech投資和第三搖滾企業和新投資者代理資本,禮來公司,紀念斯隆凱特林癌症中心(MSK)、諾華、館資本和ShangBay資本。結合融資,克雷格·d·戈登,醫學博士,創始人、首席執行官和Chief Investment Officer of GordonMD® Global Investments LP, and Irena Melnikova, Ph.D., Partner at Pfizer Ventures, have joined the Flare Therapeutics Board of Directors. “Our investor support is testament to the rapid progress our team has made since launch in advancing the only company focused on rationally designing transcription factor targeting therapies,” said Amit Rakhit, M.D., MBA, President and Chief Executive Officer of Flare Therapeutics. “This will be a pivotal year for Flare as we progress our first precision oncology program, FX-909, into the clinic, continue to expand our collection of druggable transcription factor targets, and build a pipeline of potentially first-in-class therapies against genetically validated transcription factor targets for cancer.” Proceeds from the financing will support a planned clinical trial in 2023 for FX-909, a small molecule inhibitor targeting the PPARG transcription factor, in patients with advanced urothelial cancer, as well as the advancement of a pipeline of novel transcription factor targets in oncology, including nomination of at least one additional development candidate from the company’s research pipeline in 2024. “Transcription factors have long been viewed as prime therapeutic targets playing a key role in a broad range of diseases, particularly cancers, where they represent one-third of all oncogenes. While targeting transcription factors has the potential for incredible impact, their complex structure makes them notoriously difficult to drug, requiring a new approach and new thinking,” said Rob Sims, Ph.D., Co-founder and Chief Scientific Officer of Flare Therapeutics. “From the very beginning, we knew this would require a world-class, cross-disciplinary team to not only think creatively about how to design the platform, but also how to apply translational insights to ensure efficient drug development at scale.” The Flare drug discovery platform is a powerful engine driving the systematic identification of switch sites, or druggable pockets within transcription factor complexes that dictate conformation and function. This is achieved through a broad and comprehensive approach that layers chemoproteomics, functional biochemistry, covalent chemistry and genetic insights to gain a deeper understanding of the structural underpinnings driving transcription factor function, and a proprietary library of compounds designed to modulate transcription factor behavior. “Flare has taken on one of the most formidable challenges in drug discovery – drugging transcription factors,” said Craig D. Gordon, M.D., Founder, Chief Executive Officer and Chief Investment Officer of GordonMD® Global Investments LP. “The company is making impressive strides enabled by its platform, which to date has successfully identified more than 150 switch sites across the majority of transcription factor families, providing opportunities to treat a broad range of diseases.” “We believe Flare’s differentiated and comprehensive approach to uncovering, targeting and systematically drugging switch sites on transcription factors may unlock the therapeutic potential of this class of targets, not only in oncology but in other indications as well,” said Irena Melnikova, Ph.D., Partner at Pfizer Ventures. “As a member of the board, I look forward to supporting the company in their mission to bring new medicines to patients in need.” About Flare Therapeutics Inc. Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus in precision oncology. Flare’s proprietary engine is founded on the identification of novel druggable pockets, or ‘switch sites’, within transcription factor complexes that solve for where to drug and how to tune gene expression to discover small molecule precision medicines for cancer and other diseases. The team has rapidly advanced an emerging pipeline of assets and plans to advance its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG into the clinic in 2023 in individuals with locally advanced or metastatic urothelial cancer. For more information, please visit www.flaretx.com .
拳擊手資本投資
124年投資
拳擊手的資本了124年投資。他們最新的投資耀斑療法作為他們的一部分B係列在2023年3月3日。
拳擊手資本投資活動
日期 |
輪 |
公司 |
量 |
新的嗎? |
共同投資者 |
來源 |
---|---|---|---|---|---|---|
3/22/2023 |
B係列 |
耀斑療法 |
123美元 |
沒有 |
6 |
|
2/22/2023 |
管- III |
Abivax |
137.85美元 |
是的 |
1 |
|
11/2/2022 |
一個係列 |
Lusaris療法 |
60美元 |
是的 |
拳擊手資本,深入跟蹤資本,RA資本管理,未披露的投資者,和Venrock醫療Capital Partners |
12 |
11/2/2022 |
A - II係列 |
|||||
9/7/2022 |
管 |
日期 |
3/22/2023 |
2/22/2023 |
11/2/2022 |
11/2/2022 |
9/7/2022 |
---|---|---|---|---|---|
輪 |
B係列 |
管- III |
一個係列 |
A - II係列 |
管 |
公司 |
耀斑療法 |
Abivax |
Lusaris療法 |
||
量 |
123美元 |
137.85美元 |
60美元 |
||
新的嗎? |
沒有 |
是的 |
是的 |
||
共同投資者 |
拳擊手資本,深入跟蹤資本,RA資本管理,未披露的投資者,和Venrock醫療Capital Partners |
||||
來源 |
6 |
1 |
12 |
拳擊手資本投資退出
43投資退出
拳擊手資本有43投資組合出口。他們最新的投資退出活躍療法 在2023年2月23日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。
|
收購者 |
來源 |
---|---|---|---|---|---|
2/23/2023 |
反向收購 |
4 |
|||
9/15/2022 |
首次公開募股 |
公共 |
18 |
||
8/10/2022 |
Acq -待定 |
2 |
|||
拳擊手資本團隊
7團隊成員
拳擊手資本有7 團隊成員,包括當前的創始人,首席執行官,亞倫·戴維斯。
的名字 |
工作經曆 |
標題 |
狀態 |
---|---|---|---|
亞倫·戴維斯 |
|
創始人、首席執行官 |
當前的 |
的名字 |
亞倫·戴維斯 |
||||
---|---|---|---|---|---|
工作經曆 |
|
||||
標題 |
創始人、首席執行官 |
||||
狀態 |
當前的 |
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。